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Background: Predicting response to anti-TNF alpha inhibitors (TNFi)
in RA patients is challenging. Therefore there is a high need for
identification of biomarkers of clinical outcome to guide therapeutic
decisions. A number of studies suggested that response to TNFi may
partly be explained by modulation of synovial ectopic lymphocytic
aggregates (ELN) within the synovial tissue. Certolizumab pegol is a
pegylated fully humanized TNFi. At present data regarding in vivo
effects on pathobiological responses within the synovial membrane of
patients with RA are limited. In particular, whether specific synovial
pathotypes predict response to treatment is unknown. The aim of this
study is to investigate whether the presence of synovial ELN at
baseline predicts clinical response to treatment with certolizumab
pegol in RA patients.
Methods: A cohort of biologic-naı¨ve RA patients who qualified for
TNFi according to NICE guidance (National Institute for Health and
Clinical Excellence, http://guidance.nice.org.uk/TA186) was recruited
at Barts and the London Hospital. Patients underwent ultrasound
guided synovial biopsy of an active joint prior to commencing therapy
with certolizumab pegol. Following 3 months of therapy, response to
treatment was assessed according to EULAR response criteria.
Paraffin embedding sequentially cut sections of synovial tissue
underwent H&E staining and immunohistochemical staining for CD20
to detect B cells. Sections were graded as either diffuse or aggregate
infiltrate as previously described. The study received local ethics
approval.
Results: Study population includes 25 RA patients, median age 54
(IQR: 4559), median disease duration 4 years (IQR: 2–8.5) and
median DAS28 6.2 (IQR: 5.7–6.8); 10 patients (40%) had an erosive
disease and 17 (68%) were seropositive for RF or anti-citrullinated
protein antibodies (anti-CCP). 18 patients (72%) responded to the
drug according to EULAR response criteria (32% were good
responders and 40% moderate responders). ELN was found in 11
patients (44%). A stepwise logistic regression analysis was performed
by entering several baseline variables: gender, age, disease duration,
number of previous DMARDs, presence of erosions, RF and anti-CCP
status, DAS28, HAQ, presence of ELN. Only presence of ELN was
identified as a potential predictor of response (Fisher exact test,
P<0.001).
Conclusion: To the authors’ knowledge, this is the first time that
clinical response to certolizumab pegol has been evaluated in
association with synovial ELN. Our work shows that the presence of
ELN may be a useful predictor of primary clinical response to
certolizumab pegol treatment, in line with previous data observed for
other TNFi, suggesting that histopathology could be considered in the
future as a potential key tool to guide therapeutic decisions for RA
patients.
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Background: Cardiovascular (CV) risk is increased among patients
with RA and is comparable to that observed for patients with type 2
diabetes, largely driven by the high systemic inflammatory burden
associated with RA. The heightened inflammatory state in RA is
thought to account for a lipid paradox, in which serum cholesterol is
inversely related to inflammation in patients with untreated RA.
Suppression of disease activity and inflammation with RA therapies,
including tocilizumab (TCZ), has been associated with increases in
serum lipid levels in RA patients, and is thought to reflect a
normalization of lipid levels to those seen in the general population.
To ascertain what impact TCZ may have on cholesterol levels in the
absence of inflammation, the impact of therapeutic and supra-
therapeutic doses of TCZ on cholesterol levels in healthy subjects
were examined.
Methods: This study was conducted as a single dose, randomized,
double-blind, placebo-controlled, parallel group study investigating
therapeutic and a supra-therapeutic doses of TCZ. Healthy subjects
were randomized 1:1:1 to placebo (PBO), TCZ 10 mg/kg, or TCZ
20 mg/kg, and received a single i.v. dose on Day 1. The dose of 10 mg/
kg, given as a single dose, was selected because this dose mimics the
102 TABLE 1. Summary of change from baseline of cholesterol levels by study treatment
Change from BL, mean (S.D.),
mmol/l
Scheduled visit (day)
1 2 3 5 8 11 15 22 29 50
TCh
PBO (n¼29)a –0.16 (0.36) –0.01 (0.41) 0.19 (0.44) –0.04 (0.48) 0.07 (0.57) –0.22 (0.51) 0.11 (0.72) –0.04 (0.60) –0.07 (0.60) –0.15 (0.53)
TCZ 10 mg/kg (n¼ 30)a –0.17 (0.27) 0.02 (0.33) 0.19 (0.38) 0.11 (0.35) 0.30 (0.37) 0.22 (0.38) 0.16 (0.51) 0.05 (0.49) 0.13 (0.47) –0.10 (0.39)
TCZ 20 mg/kg (n¼ 31)a –0.19 (0.24) –0.03 (0.28) 0.16 (0.42) 0.08 (0.47) 0.31 (0.47) 0.21 (0.47) 0.39 (0.56) 0.22 (0.63) 0.25 (0.55) 0.22 (0.47)
HDL
PBO (n¼29)a –0.07 (0.24) –0.05 (0.23) –0.01 (0.22) –0.02 (0.22) 0.02 (0.25) –0.04 (0.25) 0.06 (0.26) 0.02 (0.25) 0.02 (0.20) 0.00 (0.19)
TCZ 10 mg/kg (n¼ 30)a –0.07 (0.11) –0.09 (0.12) –0.11 (0.12) –0.13 (0.14) –0.08 (0.13) –0.09 (0.17) –0.02 (0.15) –0.02 (0.14) 0.02 (0.16) –0.01 (0.14)
TCZ 20 mg/kg (n¼ 31)a –0.08 (0.08) –0.11 (0.11) –0.11 (0.14) –0.10 (0.15) –0.05 (0.19) –0.11 (0.19) –0.03 (0.21) –0.01 (0.22) 0.02 (0.22) 0.04 (0.14)
LDL
PBO (n¼29)a –0.11 (0.43) –0.11 (0.43) 0.05 (0.53) 0.00 (0.50) 0.04 (0.56) –0.18 (0.47) 0.06 (0.59) –0.11 (0.49) –0.09 (0.47) –0.15 (0.51)
TCZ 10 mg/kg (n¼ 30)a –0.13 (0.21) –0.03 (0.32) 0.08 (0.33) 0.13 (0.35) 0.33 (0.38) 0.22 (0.37) 0.12 (0.40) –0.03 (0.46) 0.08 (0.44) –0.09 (0.40)
TCZ 20 mg/kg (n¼ 31)a –0.15 (0.24) –0.02 (0.30) 0.10 (0.37) 0.16 (0.42) 0.39 (0.40) 0.23 (0.42) 0.35 (0.50) 0.09 (0.55) 0.23 (0.45) 0.14 (0.42)
aNumber reflects those subjects who received a study treatment dose. Mean (S.D.).
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average therapeutic TCZ exposure (AUC, Cmax) at steady-state of an
8 mg/kg dose given every 4 weeks to an RA patient. Serum levels of
total cholesterol (TCh), high-density lipoprotein-cholesterol (HDL) and
low-density lipoprotein-cholesterol (LDL) were assessed after a 12-
hour fast at baseline (BL), days 1, 2, 3, 4, 5, 8, 11, 15, 22, 29, and
follow-up (Day 502).
Results: Administration of a single dose of TCZ resulted in a transient
small increase in TCh and LDL, tending to peak around Day 8 for both
TCZ groups. The magnitude of these increases in healthy subjects
were markedly less than those reported for RA patients treated with
TCZ and by Day 50, levels of TCh, HDL, LDL in the 10 mg/kg group had
returned to, or were lower than, baseline levels (Table 1). Mean values
for TCh, HDL, and LDL were within the normal range for all groups.
Conclusion: There were no meaningful increases in TCh, HDL or LDL
in healthy subjects with either a single therapeutic or supra-therapeutic
dose of TCZ. This observation is supportive of the notion that the
reported elevation of cholesterol levels with TCZ in RA patients is a
consequence of suppression of the inflammatory burden and the
return of cholesterol levels towards a non-inflammatory state, as found
in the general population.
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Background: In the RAPID1 randomized controlled trial (RCT),
certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52
weeks provided rapid improvements in signs and symptoms and
inhibition of radiographic damage in patients with active RA. Here we
examine the safety and efficacy of CZP plus MTX over 5 years in RA.
Methods: Eligible patients were treated in the open-label extension
(OLE) to RAPID1 (NCT00175877) with CZP 400 mg Q2W, reduced to
200 mg Q2W after 6 months, plus MTX. Primary objective of the OLE
was to monitor safety; secondary objective was to assess efficacy.
Combined safety data from RCT and OLE are presented to Wk334 for
all patients receiving 1 dose of CZP in RCT or OLE (Safety
population, N¼958). ACR20/50/70, DAS28 (ESR) and HAQ-DI are
reported to Wk256 for CZP patients who completed the 52-week RCT
(CZP Completers, N¼508) and for all patients randomized to CZP
400 mg or 200 mg in RCT (ITT population, N¼783). Change from
baseline in modified Total Sharp Score (mTSS) and percentage of
patients with radiographic non-progression (definition: mTSS change
from RCT baseline 0.5) are reported to Wk148 for CZP Completers.
Missing categorical data were imputed by modified non-responder
imputation, continuous data by last observation carried forward, and
radiographic data by linear extrapolation. Kaplan-Meier analysis was
used to estimate patient retention.
Results: Overall event rate per 100 patient-years (ER) of AEs was
290.4 and SAEs was 20.3 (serious infections¼5.9; total exposure
[including 84-day safety follow-up period]: 3,732 patient-years). The
most common AEs were urinary tract infection (ER¼7.9), nasophar-
yngitis (ER¼ 7.3) and upper respiratory tract infection (ER¼7.3). 177
patients (18.5%) experienced an AE leading to withdrawal (incidence
rate per 100 patient-years [IR]¼4.8). 21 (2.2%) experienced an AE
leading to death (IR¼0.6) (including 5 malignancies, 5 cardiac
disorders, 3 infections). Kaplan-Meier estimators of patient retention
(ITT population) at Wks52, 100, 150, 200 and 256 were 84.4%, 73.4%,
66.8%, 61.2% and 55.3%, respectively, for withdrawal due to any
reason, and 86.5%, 78.9%, 76.0%, 72.6% and 68.7%, respectively,
for withdrawal due to AEs or lack of efficacy. ACR20/50/70 response
rates for CZP Completers and ITT population were maintained to
Wk256 (74.4%/57.3%/39.6% and 59.0%/43.7%/28.8%, respectively),
as were DAS28 (ESR) remission rates (25.2% and 20.3%), improve-
ments in DAS28 (ESR) (mean values: 3.43 and 3.83; mean change from
baseline: 3.49 and 3.08) and HAQ-DI (mean values: 0.90 and 1.00;
mean change from baseline: 0.77 and 0.66). The rate of radio-
graphic progression in CZP-treated patients did not change over time
(mean mTSS change from RCT baseline to Wk52¼0.27, to
Wk148¼ 0.77; proportion achieving radiographic non-progression at
Wk52¼ 76.5%, Wk148¼68.9%).
Conclusion: CZP plus MTX provided a favourable risk-benefit profile
over 5 years of treatment in patients with active RA. No new safety
signals were identified.
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Background: Monitoring disease activity with composite scores such
as DAS-28 is fundamental to the treat to target strategy in RA. NICE
guidance recommends DAS-28 is measured regularly at clinic visits in
patients with established disease to guide treatment changes and
monthly in patients with recent onset RA until treatment has controlled
the disease to an agreed target. Presented are the results of a
completed audit cycle evaluating guideline adherence at Weston
General Hospital and three simple low-cost initiatives that doubled
DAS-28 performance.
Methods: The original audit was conducted January-March 2012.
Case notes of 10 randomly selected RA patients seen by each doctor
and specialist nurse were audited. The following DAS-28 information
was collected: target set (all patients); baseline performed (new RA
diagnosis); score in clinic and monthly repeat until disease control
(recent onset RA with disease duration<1 year); score in clinic
(established RA with disease duration>1 year). The re-audit was
conducted January-February 2013. Initiatives between audits were:
clinician education session featuring discussion on audit results and
importance of DAS-28; practical session comprising training video on
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